首页> 美国卫生研究院文献>Biologics : Targets Therapy >Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up

【2h】

Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up

机译：中度至重度类固醇难治性溃疡性结肠炎患者中阿达木单抗（仿制药）的疗效和安全性：24周随访中资源受限情况下的现实生活结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Adalimumab (ADA) is approved for the management of lcerative colitis (UC) not responding to conventional therapy. Use of biologics in resource-constrained settings is very challenging. Currently, real-life data on the safety and efficacy of ADA biosimilar (Exemptia) in steroid-refractory UC patients are limited.

机译：阿达木单抗（ADA）被批准用于治疗对传统疗法无反应的溃疡性结肠炎（UC）。在资源有限的环境中使用生物制剂非常具有挑战性。目前，有关类固醇难治性UC患者的ADA生物仿制药（Exemptia）的安全性和有效性的实际数据有限。

著录项

期刊名称 Biologics : Targets Therapy
作者
Alok Chandra; Ravi Kanth; Sandeep Thareja;
展开▼
作者单位

展开▼
年(卷),期 2019(13),-1
年度 2019
页码 -1
总页数 10
原文格式 PDF
正文语种
中图分类生物学;
关键词
ulcerative colitis; steroid refractory; adalimumab; biosimilar; exemptia;

机译：溃疡性结肠炎;难治性类固醇;阿达木单抗;生物仿制药;豁免;

相似文献

外文文献
中文文献

1. Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up [J] . Alok Chandra, Ravi Kanth, Sandeep Thareja Biologics: Targets and Therapy . 2019,第1期

机译：Adalimalab BioSimilar（exemprecia）在中度至严重的类固醇 - 难治性溃疡性结肠炎患者中的疗效和安全性：24周后的资源受限环境中的现实生活结果
2. Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis [J] . Midha Vandana, Mahajan Ramit, Mehta Varun, Intestinal research. . 2018,第1期

机译：阿达木单抗仿制药免除作为诱导疗法治疗中重度溃疡性结肠炎的疗效和安全性
3. Response to Jani et al et al . A prospective, randomized, doubleblind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis [J] . Kane Barry International journal of rheumatic diseases . 2017,第Suppla1期

机译：回应Jani等人。前瞻性，随机，双卷发，多期，并行组，活性控制研究，用于比较生物仿毒性Adalimalab（exemptia; Zrc-3197）和患者患者的疗效和安全性患者类风湿性关节炎患者的疗效和安全性
4. A Correlational Study between Hospital Patient Safety Culture and Computer Self-Efficacy among Nurses in a Hospital Setting. [D] . Joseph, Jean Marc. 2015

机译：医院环境中护士对医院患者安全文化与计算机自我效能的相关性研究。
5. Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis [O] . Vandana Midha, Ramit Mahajan, Varun Mehta, 2018

机译：阿达木单抗仿制药免除作为诱导疗法治疗中重度溃疡性结肠炎的疗效和安全性
6. >Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up [O] . Alok Chandra, Ravi Kanth, Sandeep Thareja 2019

机译：> Adalimalab BioSimilar（exemptia）在中度至严重的类固醇 - 难治性溃疡性结肠炎患者中的疗效和安全性：24周后的资源受限环境中的现实生活结果

Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up

摘要

著录项

相似文献

相关主题

期刊订阅